Stock RLMD RELMADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Relmada Therapeutics, Inc. OTC Markets

Equities

RLMD

US75955J4022

Real-time Estimate Cboe BZX
Other stock markets
 11:04:09 17/07/2024 pm IST 		5-day change 1st Jan Change
3.665 USD 0.00% Intraday chart for Relmada Therapeutics, Inc. +8.91% +139.13%
01/07 Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell Microcap Growth Index CI
01/07 Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell 3000E Growth Index CI

Insiders

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor
MT
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer
CI
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board
CI
Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors
CI
Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer
CI
Nurosene Health Names Chief Innovation and Regulatory Officer
MT
Relmada Therapeutics, Inc. Appoints John Hixon as Head of Commercial
CI
Insider Trends: Insider 90-Day Selling Trend Extended at Relmada Therapeutics
MT
Insider Trends: Insider Prolongs 90-Day Selling Trend at Relmada Therapeutics
MT
Insider Trends: Insider Prolongs Selling Trend at Relmada Therapeutics
MT
Insider Trends: Relmada Therapeutics Sees 90 Days of Insider Buying Trend Interrupting with Share Sale
MT
Insider Trends: 90-Day Insider Selling Trend Extended at Relmada Therapeutics
MT
Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and Development
CI
Relmada Therapeutics Announces Appointments of New Executive
CI
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
CI
Relmada Therapeutics, Inc. Appoints Marc de Somer, Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
CI
Relmada Therapeutics, Inc. Announces Management Changes
CI
Relmada Therapeutics, Inc. Announces Management Changes
CI
Relmada Therapeutics, Inc. Announces Management Changes
CI
Relmada Therapeutics, Inc. Appoints Gina Diguglielmo as Vice President and Head of Clinical Operations
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RLMD Stock
  4. RLMD Stock
  5. News Relmada Therapeutics, Inc.
  6. Insiders